Introduction
Under the US law, a drug is any substance (other than a food or device), which is used in the diagnosis, cure, relief, treatment or prevention of disease, or intended to affect the structure or function of the body. This comprehensive definition is important for legal purposes, but simply a drug can be defined as any chemical that affects the body and its processes. The development of any potential drug begins with years of scientific study to determine the biochemistry behind a disease, for which pharmaceutical intervention is possible. The result is the determination of specific receptors (targets) that must be modulated to alter their activity by some means. After target identification, the goal then is to find compounds that interact with the receptor by mass screening (lead). From this point onward, a cycle of iterative refinement and testing continues until a drug is developed that undergoes clinical trials. The techniques used to refine drugs are combinatorial and structure-based design. After successful clinical phase, the drug is subjected to approval by regulatory authorities and then marketed. The modern-day drug discovery pipeline is shown in Figure 1 .
A B S T R A C T
The process of drug discovery is very complex and requires an interdisciplinary effort to design effective and commercially feasible drugs. The objective of drug design is to find a chemical compound that can fit to a specific cavity on a protein target both geometrically and chemically. After passing the animal tests and human clinical trials, this compound becomes a drug available to patients. The conventional drug design methods include random screening of chemicals found in nature or synthesized in laboratories. The problems with this method are long design cycle and high cost. Modern approach including structure-based drug design with the help of informatic technologies and computational methods has speeded up the drug discovery process in an efficient manner. Remarkable progress has been made during the past five years in almost all the areas concerned with drug design and discovery. An improved generation of softwares with easy operation and superior computational tools to generate chemically stable and worthy compounds with refinement capability has been developed. These tools can tap into cheminformation to shorten the cycle of drug discovery, and thus make drug discovery more cost-effective. A complete overview of drug discovery process with comparison of conventional approaches of drug discovery is discussed here. Special emphasis is given on computational approaches for drug discovery along with salient features and applications of the softwares used in de novo drug designing.
Factors affecting drug discovery
There are a number of factors that affect the drug discovery and development process. Important ones are as follows:
Medicinal objective: In general, more precise the medicinal objective, the less likely it is to develop a new drug; for example, it is easy to develop an antacid but much more difficult is to develop specific proton-pump inhibitor. Thus, the medicinal requirements affect the likelihood of success or failure in new drug discovery.
Ability of Medicinal chemist:
The attributes of the chemist will influence the outcome of evolving new drugs on the basis of knowledge of chemistry of lead molecule and biology of diseased state.
Screening facilities: A successful and rapid mass screening mainly depends on the capacity to evaluate a large number of compounds and detect potentially clinically useful drugs in a very short span of time.
Drug development facility: Good facilities with interdisciplinary efforts by chemistry, biology, pharmacy and medical groups are necessary for drug development.
Cost of new drug:
The following three factors affect the cost of drug development-(i) Number of compounds synthesized: Of the about 5000-10,000 compounds studied, only one drug reaches the market. (ii) Nature of the lead molecule: Cost of production will be high if the lead molecule is prepared by an expensive route. (iii) Standards required for new drugs: The standards required by regulatory authorities prior to release of a drug into the market have increased dramatically. In the discovery phase, each drug cost about $350 million. The Food and Drug Association processes I, II and III cost another $150 million. This brings the total to about $500 million for each drug put on to the market for consumers.
Due to these factors, the process of drug discovery is undergoing a complete overhaul to be cost-effective and to meet the supply and demand fundamentals.
Approaches for drug discovery
Evidence of the use of medicines and drugs can be found as far back in time as 3100 BC. The current scenario of development of new drugs needs no emphasis in light of the current global situation of health and disease. For the majority of time, drug discovery has been a trialand-error process. Conventionally, the process of drug development has revolved around an almost blind screening approach, which was very time-consuming and laborious. The disadvantages of conventional drug discovery as well as the allure of a more deterministic approach to combat disease have led to the concept of "Rational drug design" in the 1960's. New understanding of the quantitative relationship between structure and biological activity ushered in the beginning of computeraided drug design (CADD). A comparison of conventional and modern drug discovery approach is given in Table 1 . With the introduction of integration and knowledge management solutions with the help of computers, a new era is beginning in drug discovery. The development cost will be cut by almost a third. The development times are reduced from 10-16 years to only 6-8 years.
How to design a drug?
At the onset, it is important to know what features an "ideal" drug should have. The drug i) must be safe and effective ii) should be well absorbed orally and bioavailable iii) metabolically stable and with a long half-life iv) nontoxic with minimal or no side effects v) should have selective distribution to target tissues Now a days, after knowing the detail information of the target and lead molecule, a drug is designed with the help of computer tools. This can potentially save pharmaceutical companies, government and academic laboratories alike from pursuing the "wrong" leads. Design process of a drug is given in Figure 2 .
Structure-based drug design
Structure-based drug design (SBDD) is considered as one of the most innovative and powerful approaches in drug design. SBDD is an iterative approach. It requires three-dimensional (3D) structure of the target protein, preferentially complexed with a ligand, where binding mode, affinity and confirmation of a ligand binding can be discerned. Subsequently, various methods are used to design a high-affinity inhibitor either via virtual computer screening of large compound libraries or through design and synthesis of novel ligands. Designed compounds are then tested in appropriate assays and the information is further used to guide the SBDD. Recent advances in computational methods for lead discovery include various commercially available softwares for de novo drug design, iterative design, selectivity discrimination, and estimation of ligand-binding affinities.
SBDD and emergence of structural genomics are paving the way to develop designer drugs. Two approaches to SBDD, the docking of known compounds into a target protein and de novo drug design has been merging as a single robust and powerful tool. In addition, dynamics simulation of multiple copies of molecular building blocks in the presence of a receptor molecule is also a useful strategy for drug design, In the future, SBDD will merge with high throughput and informatic technologies such as bioinformatics to design drugs with multiple homologous targets simultaneously. Dynamic combinatorial chemistry is a recently introduced supramolecular approach that uses self-assembly processes to generate libraries of chemical compounds. In contrast to the stepwise methodology of classical combinatorial techniques, dynamic combinatorial chemistry allows for the generation of libraries based on the continuous interconversion between the library constituents. Spontaneous assembly of the building blocks through reversible chemical reactions virtually encompasses all possible combinations, and allows the establishment of adaptive processes owing to the dynamic interchange of the library constituents. Addition of the target ligand or receptor creates a driving force that favors the formation of the best-binding constituent-a self-screening process that is capable, in principle, of accelerating the identification of lead compounds for drug discovery.
Drug design based on bioinformatics tools
The processes of designing a new drug using bioinformatics tools have opened a new area of research. However, computational techniques assist one in searching drug target and designing drug in silico, but it is time-consuming and expensive. Bioinformatics tools can provide information about potential targets that include nucleotide and protein sequencing information, homologs, mapping information, gene and protein expression data, function prediction, pathway information, disease associations, variants, structural information and taxonomic distribution among others. This means that time, effort and money can be saved in characterization of different targets. The field of bioinformatics has become a major part of the drug discovery pipeline, playing a key role for validating drug targets. By integrating data from many inter-related yet heterogeneous resources, bioinformatics can help in our understanding of complex biological processes and help improve drug discovery.
Computer-aded drug design

Role of computers
Computational tools have become increasingly important in drug discovery and design processes. Methods from computational chemistry are used routinely to study drug-receptor complexes in atomic detail and to calculate properties of small-molecule drug candidates. Tools from information sciences and statistics are increasingly essential to organize and manage the huge chemical and biological activity databases that all pharmaceutical companies now possess, and to make optimal use of these databases.
In addition, the act of generating chemical derivatives is highly amenable to computerized automation. Libraries of derivative compounds are assembled by application of targeted structure-based combinatorial chemistry from the analysis of active sites. Because of the combinatorial nature of this method, a large number of candidate structures may be possible. A computer can rapidly generate and predict the binding of all potential derivatives, creating a list of best potential candidates. In essence, computer filters all weak binding compounds, allowing the chemist to focus, synthesize, and test only the most promising ligands. Thus, using the CADD software to aid in the refinement of lead molecules is the most effective manner in which these tools can be employed. The use of computer modeling to refine structures has become standard practice in modern drug design. So the current role of computer in drug design lies in: a) Storing and retrieving information i) Structures determined experimentally by X-ray cryst allography for biological targets (enzymes) and drug molecules ii) Molecules and activities to test the affect of small structural changes on biological activity b) Information about toxicity and its relationship to structure c) Visualization of molecules i) Similarities/differences between drugs and receptors ii) Interaction between drugs and receptors d) Calculations i) Interaction strengths ii) Motion (dynamics)
Challenges in computer-aided drug design
Highly intellectual professionals with interdisciplinary knowledge of various facets of science, most importantly, biology, chemistry and computation are required for CADD and this is a major challenge for this field. In scientific computing, accuracy and processing time are always important. Thus, in order to make the calculations in a finite period of time, a plethora of assumptions, significant approximations, and numerous algorithmic shortcuts has to be used. This, in turn, greatly diminishes the calculated accuracy of any ligand receptor interaction. This remains the most significant challenge in CADD. Another problem is generation of a vast number of undesired chemical structures as there are a nearly infinite number of potential combinations of atoms and most of them are either chemically unstable, synthetically unfeasible or have higher toxicity.
Keeping in mind these shortcomings of CADD, improved generation of softwares with more user-friendly programs, superior and fast computational facilities, and creation of synthetic feasible and stable chemical compounds and with refinement feature has been developed in the last decade.
Drug design softwares
General approach
The development of a new drug starts with the design of suitable candidate compounds, so-called "Ligands," which are selected on the basis of how these compounds are recognized by the target protein and binds to it. "Ligbuild" is a powerful tool to build a legend just based on a protein structure in Brookheaven format. Performing experiments to know protein dynamics is expensive as well as time-consuming. The only alternative, computer simulation of the dynamics of molecule (MD simulation), becoming increasingly important to identify which molecular properties are important and what are the molecular interactions responsible for binding. Evaluation of binding agent is done by scoring approach. "Score" is a tool to evaluate the binding affinity of protein-ligand complex with known 3D structure. Candidate molecules are further screened out on several criteria. Permeability across the biomembrane is an important characteristic. XLOGP can calculate logP (logarithm of the partition coefficient of a solute between octanol and water) of the common organic compounds, Furthermore, XLOGP can provide detailed hydrophobicity distribution information of the molecule. PLOGP can calculate logP values of peptides along with Molecular Lipophilicity Potential (MLP) profile of a protein with known structure. A database-based predictive system is also developed to assess the risk and toxicity of the chemicals in the early stage of drug design.
The activity prediction studies on the basis of shape of the molecule include i) Fast and efficient clustering of molecules based on molecular shape ii) Field-based similarity computation of molecular structure iii) Flexible Quantitative Structure Activity Relationships (QSAR) analysis of molecules based on shape cluster
Comparative Molecular Field Analysis (CoMFA) has been widely used as a type of 3D QSAR method during the last 10 years.
Rational programs used
Drug design programs fall in one of three main categories: scanners, builders, or hybrids.
Scanners-These types of programs are used for screening of lead compounds. All database search programs fall into this category. 
